Home > News Center > Company News
- Haohai Biological Technology Announces 2022 Results2023-04-04
- Another record set! Haohai Biological Technology secures championship on many market segments again2022-06-28
- Concluded perfectly! Haohai Biological Technology’s “Artificial Vitreous Body project” wins the 2021 national disruptive technolog...2021-12-31
- The only biopharmaceutical company in Songjiang District, Shanghai! Haohai Biological Technology selected into the latest 100 best...2021-12-17
- Another “star” member added to intraocular lens product line of Haohai Biological Technology within a month2021-11-30
- The first ever domestic! Haohai Biological Technology’s preloaded hydrophilic aspherical intraocular lens approved2021-11-01
- The Third Quarterly Report for 20212021-10-29
- Haohai 1H2021 Results2021-08-27
- The first ophthalmic drug of Haohai BiologicalTechnology! The first homemade moxifloxacin hydrochloride eye drops approved by NMPA...2021-03-10
- Investing in Eirion, Haohai Biological Technology expands its “external application +classical injection” botulinum toxin product ...2021-03-03
- With acquisition of JUVA, Haohai Biological Technology’s medical aesthetics business enters an era of “medical end +consumer end” ...2021-02-21
- Haohai Biological Technology to be included in Shanghai-Hong Kong Stock Connect, effective of February 12021-01-25
- Haohai 2020 Third Quarter Results2020-10-28
- A new dermalfiller! Haohai Biological Technology launches a new high-end hyaluronic acid product “Hyalumatrix”2020-08-09
- A new breakthrough made in a revolutionary treatment protocol! Haohai officially starts clinical trial for “retinal tear blocking ...2020-08-03
Company News